# Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy (PDN)

> **NCT03297294** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 142 (actual)

## Conditions studied

- Painful Diabetic Neuropathy

## Interventions

- **DRUG:** EMA401
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03297294
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-14
- **Primary completion:** 2019-03-25
- **Final completion:** 2019-03-25
- **Target enrollment:** 142 (ACTUAL)
- **Why stopped:** Study was terminated due to animal toxicity data
- **Last updated:** 2021-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03297294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03297294, "Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy (PDN)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03297294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*